• DAergic as well as GABAergic and glutamatergic

  2022-12-15

  

  DAergic, as well as GABAergic and glutamatergic neurons, send projections to target forebrain structures, such as the nucleus accumbens (NAc) and medial prefrontal cortex (mPFC), and support diverse functional roles (Carr and Sesack, 2000a, Carr and Sesack, 2000b, Omelchenko and Sesack, 2009, Taylor

• Despite these efforts to prevent oxidative metabolic

  2022-12-15

  

  Despite these efforts to prevent oxidative metabolic degradation, and showed only marginal improvements in metabolic stability and still exhibited high plasma clearances as shown in . High molecular weight as well as relative high log values could be contributing factors to the poor PK profiles of

• In terms of the ring B

  2022-12-15

  

  In terms of the ring B C5′ position, while C5′-F (compound ) was tolerated, C5′-Me (compound ) and C5′-Cl (compound ) substitutions resulted in a loss in potency. However, the C5′-OMe substitution (compound ) resulted in a ∼3-fold increase in potency compared to . Modeling suggested a pseudo hydroge

• It is worth pointing out that phenotypes

  2022-12-15

  

  It is worth pointing out that phenotypes of in vivo HSP90β inhibition were not identical to those observed in rapsyn mutant mice (Gautam et al., 1995). Postsynaptically, junctional AChR clusters appeared fragmented, in addition to expected reduction in AChR intensity, in muscles injected with 17-AAG

• The reductase family is composed of three known isozymes wit

  2022-12-15

  

  The 5α-reductase family is composed of three known isozymes, with the types I and II being the most known. Type I isozyme, which is the dominant form, can be found in the skin, liver, kidney, brain and lung. Furthermore, it has been evidenced that type I activity is several times higher in PC than i

• An AXL decoy receptor with enhanced GAS binding properties M

  2022-12-15

  

  An AXL decoy receptor with enhanced GAS6-binding properties, MYD1, was engineered as a therapeutic tool to disrupt GAS6/AXL signaling in vivo (Kariolis et al., 2014). MYD1 was shown to block metastasis of human ovarian cancer AZ5104 and a murine breast cancer cell line in grafting assays in mice. T

• br Materials and methods br Acknowledgement This work was

  2022-12-14

  

  Materials and methods Acknowledgement This work was supported by the Beijing Natural Science Foundation (Grant no. 6151001), and the National Natural Science Foundation of China (Grant no. 31572516). Introduction Staphylococcus aureus is an important microorganism responsible for both clin

• br Conclusions The present protocol for localizing

  2022-12-14

  

  Conclusions The present protocol for localizing or “spotting” the site of action of an antioxidant in a micro-heterogeneous medium is based on the differences in its reactivity vis-à-vis the series of amphiphobic TEMPO derivatives 1a–f. Plots of the relative antioxidant effectiveness of a given A

• br Materials and methods br

  2022-12-14

  

  Materials and methods Results In order to evaluate changes in the amount of PKC-θ expressed by MEL cells at different stages of the cell cycle, we measured the level of the kinase in cells collected from cultures containing 90% of cells in the interphase or 80% cells synchronized at the metaph

• Using this cheese mimicking matrix we

  2022-12-14

  

  Using this cheese-mimicking matrix, we screened the antifungal activity of 44 LAB fermented milk-based products and 23 LAB isolates used as protective cultures against 4 fungal targets. The LAB were obtained from the culture collections of CIRM-BIA (Centre International de Ressources Microbienne-Bac

• VEGFR inhibition using sunitinib does not

  2022-12-14

  

  VEGFR2 inhibition using sunitinib does not result in tumor growth reduction or in a further decrease in vessel density in NDRG1 overexpressing glioma rendering these tumors intrinsically resistant to antiangiogenic treatment. Intrinsic resistance to antiangiogenic therapy is defined as a non-respons

• Regardless of the initial treatment most patients with advan

  2022-12-14

  

  Regardless of the initial treatment, most patients with advanced NSCLC experience relapse and disease progression [15]. A subpopulation of immediate concern and clinical need is patients who have advanced NSCLC that is especially aggressive, which is usually defined as disease that rapidly progresse

• br Eprosartan The AT R antagonist eprosartan

  2022-12-14

  

  Eprosartan The AT1R antagonist eprosartan is approved for the treatment of essential TPEN and may be administered using a convenient once-daily regimen. The drug is a well-tolerated and effective antihypertensive agent with benefit in the secondary prevention of cerebrovascular events, independe

• AR Vs are truncated AR proteins lacking the AR ligand

  2022-12-14

  

  AR-Vs are truncated AR proteins lacking the AR ligand-binding domain (AR-LBD) [6]. While AR-Vs have frequently been detected in CRPC, their expression and functional role in benign prostate tissues and primary prostate cancers is not readily apparent. Structural rearrangements in the AR gene and alt

• The loss of synaptic proteins such as synaptophysin from

  2022-12-14

  

  The loss of synaptic proteins such as synaptophysin from the ret pathway is indicative of synapse degeneration and provided a good correlate of the degree of dementia in AD [12], [13], [14]. Consequently, the loss of synaptic proteins from cultured primary neurons incubated with Aβ provides a usefu

14690 records 313/980 page Previous Next First page 上5页 311312313314315 下5页 Last page